209 related articles for article (PubMed ID: 35115614)
1. The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Okura T; Fujioka Y; Nakamura R; Kitao S; Ito Y; Anno M; Matsumoto K; Shoji K; Matsuzawa K; Izawa S; Okura H; Ueta E; Kato M; Imamura T; Taniguchi SI; Yamamoto K
Sci Rep; 2022 Feb; 12(1):1896. PubMed ID: 35115614
[TBL] [Abstract][Full Text] [Related]
2. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
So A; Sakaguchi K; Okada Y; Morita Y; Yamada T; Miura H; Otowa-Suematsu N; Nakamura T; Komada H; Hirota Y; Tamori Y; Ogawa W
Endocr J; 2020 May; 67(5):501-507. PubMed ID: 32023587
[TBL] [Abstract][Full Text] [Related]
3. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
6. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
7. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease.
Jensen AH; Ytting H; Werge MP; Rashu EB; Hetland LE; Thing M; Nabilou P; Burisch J; Bojsen-Møller KN; Junker AE; Hobolth L; Mortensen C; Tofteng F; Bendtsen F; Møller S; Vyberg M; Serizawa RR; Gluud LL; Wewer Albrechtsen NJ
Am J Physiol Gastrointest Liver Physiol; 2024 Jun; 326(6):G736-G746. PubMed ID: 38625142
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
9. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
[TBL] [Abstract][Full Text] [Related]
10. Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction.
Keyhani-Nejad F; Barbosa Yanez RL; Kemper M; Schueler R; Pivovarova-Ramich O; Rudovich N; Pfeiffer AFH
Peptides; 2020 Mar; 125():170231. PubMed ID: 31870938
[TBL] [Abstract][Full Text] [Related]
11. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
[TBL] [Abstract][Full Text] [Related]
13. SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis.
Zhu X; Lin C; Li L; Hu S; Cai X; Ji L
Eur J Pharmacol; 2021 Jul; 903():174145. PubMed ID: 33957085
[TBL] [Abstract][Full Text] [Related]
14. Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance.
Lin PJ; Borer KT
PLoS One; 2016; 11(10):e0165378. PubMed ID: 27798656
[TBL] [Abstract][Full Text] [Related]
15. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
[TBL] [Abstract][Full Text] [Related]
16. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
[TBL] [Abstract][Full Text] [Related]
17. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
18. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
20. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
